Rhythm Pharmaceuticals Inc. announced the presentation of four datasets at ObesityWeek® 2025, including results from the Phase 3 TRANSCEND trial evaluating setmelanotide in patients with acquired hypothalamic obesity. Data presented showed that setmelanotide achieved significant reductions in BMI, both in patients receiving concomitant GLP-1 therapy and those not on GLP-1 therapy. Additional analyses indicated clinically meaningful improvements in cardiometabolic parameters after 52 weeks of setmelanotide treatment. Patient and caregiver interviews from the TRANSCEND trial also reported beneficial changes in hunger, weight, energy levels, and physical activity. The results were presented at ObesityWeek® 2025 in Atlanta, GA.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhythm Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571611-en) on November 10, 2025, and is solely responsible for the information contained therein.